- Home
- CANF vs CNVS Comparison
CANF vs CNVS Comparison
Compare CANF & CNVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- CNVS
- Stock Information
- Founded
- CANF 1994
- CNVS 2000
- Country
- CANF Israel
- CNVS United States
- Employees
- CANF N/A
- CNVS N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- CNVS Consumer Electronics/Video Chains
- Sector
- CANF Health Care
- CNVS Consumer Discretionary
- Exchange
- CANF Nasdaq
- CNVS Nasdaq
- Market Cap
- CANF 13.5M
- CNVS N/A
- IPO Year
- CANF N/A
- CNVS 2003
- Fundamental
- Price
- CANF $1.03
- CNVS $6.75
- Analyst Decision
- CANF Strong Buy
- CNVS Buy
- Analyst Count
- CANF 2
- CNVS 1
- Target Price
- CANF $14.00
- CNVS $10.00
- AVG Volume (30 Days)
- CANF 144.2K
- CNVS 584.6K
- Earning Date
- CANF 08-29-2025
- CNVS 08-13-2025
- Dividend Yield
- CANF N/A
- CNVS N/A
- EPS Growth
- CANF N/A
- CNVS N/A
- EPS
- CANF N/A
- CNVS 0.16
- Revenue
- CANF $674,000.00
- CNVS $78,181,000.00
- Revenue This Year
- CANF $461.72
- CNVS N/A
- Revenue Next Year
- CANF N/A
- CNVS N/A
- P/E Ratio
- CANF N/A
- CNVS $42.50
- Revenue Growth
- CANF N/A
- CNVS 59.13
- 52 Week Low
- CANF $0.98
- CNVS $0.72
- 52 Week High
- CANF $4.69
- CNVS $7.39
- Technical
- Relative Strength Index (RSI)
- CANF 43.30
- CNVS 84.27
- Support Level
- CANF $1.00
- CNVS $3.72
- Resistance Level
- CANF $1.09
- CNVS $7.23
- Average True Range (ATR)
- CANF 0.03
- CNVS 0.56
- MACD
- CANF 0.00
- CNVS 0.22
- Stochastic Oscillator
- CANF 45.00
- CNVS 83.11
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).